Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50-70% of patients usi...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-03, Vol.15 (6), p.1663
Main Authors: Chiang, Ting-Yu, Hsu, Hung-Chih, Chern, Yih-Jong, Liao, Chun-Kai, Hsu, Yu-Jen, Tsai, Wen-Sy, Hsieh, Pao-Shiu, Lin, Yu-Fen, Lee, Hsiu-Lan, You, Jeng-Fu
Format: Article
Language:English
Subjects:
Acne
Age
Body mass index
Cancer
Cancer therapies
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Dosage and administration
Drug therapy
Enzyme inhibitors
Epidermal growth factor receptors
Females
Gender differences
Growth factors
Males
Metastases
Metastasis
Patient outcomes
Prognosis
Skin
Survival
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50-70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS ( < 0.001) and PFS ( < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; -value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15061663